Athena Athena

X

Find Drugs in Development News & Deals for Daprodustat

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

0

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)

0

INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Uploaded Dossiers

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

DIGITAL CONTENT

Blog #PharmaFlow

0

News

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

  • Development Update

Details:

Jesduvroq (daprodustat) is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) used for the treatment of symptomatic anaemia associated with chronic kidney disease (CKD) in adults on chronic maintenance dialysis.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: Jesduvroq

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 26, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Jesduvroq (daprodustat), a HIF-PHI, which inhibis of oxygen-sensing prolyl hydroxylase enzymes stabilises hypoxia-inducible factors, which can lead to transcription of erythropoietin and other genes involved in the correction of anaemia.


Lead Product(s): Daprodustat

Therapeutic Area: Nephrology Product Name: Jesduvroq

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Duvroq (daprodustat), a HIF-PHI, belongs to a novel class of oral medicines being studied for the treatment of anaemia of CKD in adult patients not on dialysis and on dialysis.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: Duvroq

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Duvroq (daprodustat), a HIF-PHI, belongs to a novel class of oral medicines being studied for the treatment of anaemia of CKD in adult patients not on dialysis and on dialysis.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: Duvroq

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 27, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Studies demonstrated that Duvroq (daprodustat) improved or maintained Hb within target level, and primary safety analysis of populations showed that daprodustat achieved non-inferiority of MACE compared to standard of care, both non-dialysis and dialysis patient settings.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: Duvroq

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable September 06, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

Regulatory submission of daprodustat for treatment of anaemia of chronic kidney disease based on ASCEND phase III clinical trial programme, consisting of five trials that all met their primary efficacy and safety endpoints in non-dialysis and dialysis patients.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: GSK1278863

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 19, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

The MAA based on positive data from ASCEND Phase III clinical trial programme for GSK1278863 (daprodustat), a HIF-PHI met co-primary efficacy and safety endpoints also, approved in Japan as Duvroq for patients with renal anaemia.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: GSK1278863

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 01, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

GSK1278863 (Daprodustat) is first oral HIF-PHI to clearly show positive efficacy, along with no increased cardiovascular risk as assessed in primary analysis. Daprodustat is currently approved in Japan as Duvroq for patients with renal anaemia.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: GSK1278863

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator:

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 05, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
  • Development Update

Details:

The most commonly reported adverse events in patients receiving daprodustat across the ASCEND programme included hypertension, diarrhoea, dialysis hypotension, peripheral edema, and urinary tract infection.


Lead Product(s): Daprodustat

Therapeutic Area: Hematology Product Name: GSK1278863

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 16, 2021

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY